Business Context and Reporting Period
Company: HALOZYME THERAPEUTICS, INC.
Filing Type: Form 8-K (Current Report)
Date of Report: August 9, 2016
Reporting Period: Second quarter ended June 30, 2016
This filing serves as a notification that the company issued a press release on August 9, 2016, reporting its financial results for the second quarter of 2016. The press release is attached as Exhibit 99.1.
Key Financial Metrics
The provided text is a cover document (Form 8-K) and does not contain specific financial data points. It references a press release (Exhibit 99.1) for the actual figures. Consequently, the following metrics are not available in this text:
- Revenue
- Profit/Loss
- Cash Flow
- Margins
- Debt and Liquidity
Note: The filing text does not provide a clear value for any financial metric.
Material Changes
No material changes or comparative financial data are disclosed within the body of this Form 8-K. The document solely announces the issuance of the Q2 2016 results press release.
Guidance, Outlook, and Risks
This filing does not contain management commentary, forward-looking guidance, risk factors, or details on contingencies. It explicitly states that the attached press release is furnished under Item 2.02 and is not deemed "filed" for purposes of Section 18 of the Exchange Act.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release dated August 9, 2016) for actual Q2 2016 financial results.
- Verify the specific revenue, net income, and cash position figures in the attached press release, as they are absent from this summary document.
- Check for any forward-looking statements or updated guidance contained within the press release.